Rhythm Biosciences (ASX:RHY) enrolled the first physician participant in its ColoSTAT Access Program, a commercial deployment framework for its blood-based test for the detection of colorectal cancer, according to a Wednesday Australian bourse filing.

Under the program, participating clinicians receive an initial allocation of ColoSTAT tests at no cost and continued use of the test after the initial allocation is expected to be on a paid basis, the filing said. The program will be capped at 20 participants in Australia.

Rhythm Biosciences' shares jumped nearly 9% in recent trading on Wednesday.